In a world facing a post-antibiotic apocalypse, one institute in Tbilisi has been quietly perfecting the alternative for nearly a century. The Eliava Institute isn't just a health organization; it's a living relic of Soviet science that has outlasted empires and now operates as a niche global powerhouse in bacteriophage therapy.

"While the West relies on antibiotics, Georgia relies on viruses that hunt bacteria—and they've been doing it since the Cold War."

The tech stack tells a story of modernization without disruption. Ruby on Rails powers the backend—a robust, developer-friendly choice—while jQuery and Bootstrap handle the frontend. It's functional, not flashy. This isn't a startup chasing VC funding with a React-heavy SPA; it's a stable platform serving a critical medical function. The use of GSAP and Swiper suggests they care about user experience, but only where it matters.

• Niche Dominance: They own the bacteriophage conversation in Georgia and beyond
• High-Value Traffic: 49% organic search traffic indicates strong intent from researchers and patients
• Operational Efficiency: $4.7M revenue with a lean 51-person team
• Legacy Tech: Ruby on Rails stack suggests stability over hype-chasing